Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Spray Versus Placebo in Functional Improvement of Patients With Ischemic Strokes
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs TF 0023 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Techfields Pharma
- 04 Jan 2024 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 04 Jan 2024 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2024.
- 26 May 2022 Status changed from recruiting to suspended.